In this article, we will be taking a look at the 12 best healthcare stocks to buy under $30.

Mizuho health care sector strategist Jared Holz made an appearance on CNBC’s “The Exchange” on July 21 to discuss the challenges facing the healthcare industry and whether there are any opportunities in the field.

He said that it would be wonderful to occasionally cover a sector that outperforms the market, and said that he is undoubtedly upset with the current dynamics in the healthcare industry.

According to the strategist, the only times the healthcare industry has outperformed the market over the last ten years, and even then, that wasn’t a good setup, are when the market was down. Holz believes that the performance of the large-cap pharmaceutical business is significantly impacted by a cascade of problems.

He added to CNBC that nothing even comes close to this kind of pressure across the board if we go back a few decades, making this the worst the healthcare industry has ever experienced. Holz identified managed care and pharmaceuticals as the main offenders, claiming that they are bearing the most burden in terms of market capitalization.

With these trends in view, let’s look at the 12 Best Healthcare Stocks to Buy Under $30.

Our Methodology 

For our methodology, we screened stocks with a share price below $30 and ranked them according to the number of hedge fund holders as of Q1 2025, based on data from the Insider Monkey database. Additionally, we included the share price as of the most recent closing (11 August) in the subheadings for clarity.

Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).

Here is our list of the 12 best healthcare stocks to buy under $30.  

12. ImmunityBio, Inc. (NASDAQ:IBRX)

Number of Hedge Fund Holders: 10 

Share Price: $2.47 

ImmunityBio, Inc. (NASDAQ:IBRX) is among the best healthcare stocks. It is a clinical-stage biotech company developing advanced immunotherapies and vaccines targeting cancers and infectious diseases by activating immune cells such as natural killer and T cells.

A key recent milestone is the FDA-approved immunotherapy drug ANKTIVA for bladder cancer, specifically for patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) carcinoma in situ (CIS). ANKTIVA, designated a Breakthrough Therapy, is expanding its clinical use, notably with the Michael E. DeBakey VA Medical Center in Houston becoming one of the first VA hospitals to administer the treatment to veterans, a population at higher bladder cancer risk.

In Q2 2025, ImmunityBio, Inc. (NASDAQ:IBRX) reported a 60% revenue growth quarter-over-quarter, reaching $26.4 million and a year-to-date total of approximately $43 million. This growth is driven by increased commercial momentum post-approval and supported by an $80 million capital raise in July 2025 to fuel ongoing development and expansion.

ImmunityBio, Inc. (NASDAQ:IBRX) is transitioning from a clinical-stage biotech to a commercial-stage company with ANKTIVA’s expanding adoption, including recent UK regulatory approval for ANKTIVA plus BCG. The drug addresses an underserved cancer indication with the potential to reduce invasive treatments like cystectomy, backed by clinical data showing durable bladder preservation up to 36 months in responders.

11. Cronos Group Inc. (NASDAQ:CRON)

Number of Hedge Fund Holders: 13 

Share Price: $2.67 

Cronos Group Inc. (NASDAQ:CRON) is a global cannabis company operating primarily in Canada and Israel, with recognized brands like PEACE NATURALS and Spinach. The company focuses on both medicinal and recreational cannabis markets and is expanding internationally into Australia, Malta, Germany, and Switzerland.

In Q2 2025, Cronos Group Inc. (NASDAQ:CRON) reported a 21% year-over-year revenue increase to $33.5 million, driven mainly by its PEACE NATURALS brand in Israel and other international markets. Despite a net loss of $38.5 million influenced partly by foreign exchange impacts, the consolidation of its Canadian cultivation subsidiary, Cronos GrowCo, contributed $2.2 million in flower sales and helped boost gross margins from 23% to 43%.

The business strategically focuses on global markets like Israel to offset U.S. regulatory uncertainties and recently resolved an anti-dumping dispute there, stabilizing its international operations. The corporation maintains a strong liquidity position with $834 million in cash and short-term investments, supporting initiatives like an $18.5 million convertible loan investment in Canadian retailer High Tide Inc.

Looking ahead, analysts expect profitability to improve with a 50% capacity increase at GrowCo, supporting rising demand and better margins. Q3 2025 revenue is forecasted at $37.3 million with adjusted EBITDA rising to $5.6 million, reflecting operational momentum. Additionally, Cronos Group Inc. (NASDAQ:CRON) announced a $50 million share repurchase program, signaling confidence in its growth prospects.

10. Tilray Brands, Inc. (NASDAQ:TLRY)

Number of Hedge Fund Holders: 14 

Share Price: $0.92 

Tilray Brands, Inc. (NASDAQ:TLRY) is a global lifestyle and consumer goods company focused on cannabis, beverages, and wellness. In June 2025, the company launched its 2025 summer cannabis collection in Canada, featuring new THC beverages, pre-rolls, vapes, aromatic flowers, and infused edibles. This product diversification targets varied consumer preferences and reinforces Tilray’s leadership in the cannabis market.

Recently, Tilray Brands, Inc. (NASDAQ:TLRY) expanded into wellness snacks with the launch of Humble Seed Whole Wheat Protein Crackers at Whole Foods Market, marking a strategic move beyond cannabis. This launch triggered a 4.9% share price increase, an analyst upgrade, and a significant insider purchase by CEO Irwin D. Simon, reflecting strong confidence in the company’s growth direction. While not traditionally in the same category, some investors view Tilray’s wellness and pharmaceutical distribution segment as aligning with certain best healthcare stocks themes due to its role in health-oriented consumer products

the business’s diversified revenue streams now include cannabis (30%), beverages (29%), pharmaceutical and wellness product distribution (33%), and hemp-based foods (8%). This broad portfolio helps mitigate regulatory risks in the U.S. and supports long-term growth. Tilray Brands, Inc. (NASDAQ:TLRY) projects adjusted EBITDA growth of 13–31% for the fiscal year ending May 2026, which indicates optimism about expanding operations and profitability.